Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Waldenstrom Macroglobulinemia
Related studies linked through entity extraction aliases.
A Phase II Study of Doxycycline in Relapsed NHL
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
- Status
- COMPLETED
- Phase
- PHASE2
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Status
- RECRUITING
- Phase
- PHASE3
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE1
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Nonmyeloablative Allogeneic Transplant
- Status
- COMPLETED
- Phase
- NA
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE3
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A